Top

Neurological Sciences

Published in:

01-02-2021 | Migraine | Original Article

Evaluation of serum uric levels in migraine

Authors: Tamer Yazar, Hülya Olgun Yazar, Ali Aygün, Volkan Karabacak, Yavuz Altunkaynak, Dursun Kirbaş

Published in: Neurological Sciences | Issue 2/2021

Abstract

Objective

In our study, the aim was to identify the serum uric acid levels, a marker of oxidative stress, according to migraine subtypes (aura/without aura and episodic/chronic migraine).

Method

The study included 300 migraine patients and 150 healthy controls for a total of 450 individuals. Migraine and subtypes were diagnosed according to International Classification of Headache Disorders-2013 criteria. Patients were evaluated during attendance at the neurology clinic.

Results

Our patient group was 77.0% female and disease duration was 9.2 ± 7.2 years. Our control group comprised 77.3% females. The age intervals in the patient and control groups were 36.4 ± 10.4 years and 36.0 ± 8.1 years. There was no statistically significant difference between our control and patient groups in terms of age and gender (p = .937 and p = .655). The serum UA, ferritin, and urea levels in our patient group were found to be significantly low compared to the healthy control group (p < .001). The serum UA levels in the migraine and control groups were 3.7 ± 0.7 and 4.6 ± 0.7 mg/dL, respectively (p < .001). There were no statistically significant differences observed between serum uric acid levels and other blood parameters between aura/without aura and episodic/chronic migraine subtypes (p > .05).

Conclusion

Our study supports the hypothesis that the oxidative stress marker of serum uric acid levels may be associated with migraine diagnosis, concluding that serum uric acid levels were not significant for migraine subtypes.

Martami F, Razeghi Jahromi S, Togha M, Ghorbani Z, Seifishahpar M, Saidpour A (2018) The serum level of inflammatory markers in chronic and episodic migraine: a case-control study. Neurol Sci 39(10):1741–1749. https://doi.org/10.1007/s10072-018-3493-0CrossRefPubMed

Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33(9):629–808. https://doi.org/10.1177/0333102413485658CrossRef

Dodick DW (2018) A phase-by-phase review of migraine pathophysiology. Headache 58(Suppl 1):4–16. https://doi.org/10.1111/head.13300CrossRefPubMed

Malo-Urriés M, Estébanez-de-Miguel E, Bueno-Gracia E, Tricás-Moreno JM, Santos-Lasaosa S, Hidalgo-García C (2020) Sensory function in headache: a comparative study among patients with cluster headache, migraine, tension-type headache, and asymptomatic subjects. Neurol Sci. https://doi.org/10.1007/s10072-020-04384-8

Ray BK, Paul N, Hazra A, Das S, Ghosal MK, Misra AK, Banerjee TK, Chaudhuri A, Das SK (2017) Prevalence, burden, and risk factors of migraine: a community-based study from eastern India. Neurol India 65:1280–1288. https://doi.org/10.4103/0028-3886.217979CrossRefPubMed

Rapoport AM, Edvinsson L (2019) Some aspects on the pathophysiology of migraine and a review of device therapies for migraine and cluster headache. Neurol Sci 40:75–80. https://doi.org/10.1007/s10072-019-03828-0CrossRefPubMed

Ramachandran R (2018) Neurogenic inflammation and its role in migraine. Semin Immunopathol 40(3):301–314. https://doi.org/10.1007/s00281-018-0676-yCrossRefPubMed

Yigit M, Sogut O, Tataroglu Ö et al (2018) Oxidative/antioxidative status, lymphocyte DNA damage, and urotensin-2 receptor level in patients with migraine attacks. Neuropsychiatr Dis Treat 14:367–374. Published 2018 Jan 24. https://doi.org/10.2147/NDT.S156710CrossRefPubMedPubMedCentral

Chiurchiù V, Orlacchio A, Maccarrone M (2016) Is modulation of oxidative stress an answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative Diseases. Oxidative Med Cell Longev 2016:7909380–7909311. https://doi.org/10.1155/2016/7909380CrossRef

10.

Naduthota RM, Bharath RD, Jhunjhunwala K, Yadav R, Saini J, Christopher R, Pal PK (2017) Imaging biomarker correlates with oxidative stress in Parkinson’s disease. Neurol India 65:263–268. https://doi.org/10.4103/neuroindia.NI_981_15CrossRefPubMed

11.

Li JJ, Huang YH, Lin YY, Li MM, Chen YF, Cai RW (2016) The association of uric acid with leukoaraiosis. J Int Med Res 45(1):75–81. https://doi.org/10.1177/0300060516674353CrossRefPubMedPubMedCentral

12.

Geyik S, Altunısık E, Neyal AM, Taysi S (2016) Oxidative stress and DNA damage in patients with migraine. J Headache Pain 17:10. https://doi.org/10.1186/s10194-016-0606-0CrossRefPubMedPubMedCentral

13.

Erdal N, Altunkaynak Y, Altunkaynak E, Öztürk M, Mutluay B, Köksal A, Baybaş S (2005) Evaluation of lipid peroxidation representing oxidative stress in patients with migraine. Düşünen Adam 18(3):129–135

14.

Eren Y, Dirik E, Neşelioğlu S, Erel Ö (2015) Oxidative stress and decreased thiol level in patients with migraine: cross-sectional study. Acta Neurol Belg 115(4):643–649. https://doi.org/10.1007/s13760-015-0427-yCrossRefPubMed

15.

Tuncel D, Tolun FI, Gokçe M et al (2008) Oxidative stress in migraine with and without aura. Biol Trace Elem Res 126:92–97. https://doi.org/10.1007/s12011-008-8193-9CrossRefPubMed

16.

Lance JW (1993) Current concepts of migraine pathogenesis. Neurology. 43(6 Suppl 3):S11–S15PubMed

17.

Schirinzi T, DiLazzaro G, Colona VL, Imbriani P, Alwardat M, Sancesario GM et al (2017) Assessment of serum uric acid as risk factor for tauopathies. J Neural Transm (Vienna) 124(9):1105–1108. https://doi.org/10.1007/s00702-017-1743-6CrossRef

18.

Cankurtaran M, Yesil Y, Kuyumcu ME, Oztürk ZA, Yavuz BB, Halil M, Ulger Z, Cankurtaran ES, Arıoğul S (2013) Altered levels of homocysteine and serum natural antioxidants links oxidative damage to Alzheimer's disease. J Alzheimers Dis 33(4):1051–1058. https://doi.org/10.3233/JAD-2012-121630CrossRefPubMed

19.

El Ridi R, Tallima H (2017) Physiological functions and pathogenic potential of uric acid: a review. J Adv Res 8(5):487–493. https://doi.org/10.1016/j.jare.2017.03.003CrossRefPubMedPubMedCentral

20.

Yang X, Yang B, Wu M et al (2019) Association between serum uric acid levels and benign paroxysmal positional vertigo: a systematic review and meta-analysis of observational studies. Front Neurol 10:91. Published 2019 Feb 15. https://doi.org/10.3389/fneur.2019.00091CrossRefPubMedPubMedCentral

21.

Żebrowska E, Maciejczyk M, Żendzian-Piotrowska M, Zalewska A, Chabowski A (2019) High protein diet induces oxidative stress in rat cerebral cortex and hypothalamus. Int J Mol Sci 20:1547CrossRef

22.

Charles A (2018) The pathophysiology of migraine: implications for clinical management. Lancet Neurol 17(2):174–182. https://doi.org/10.1016/S1474-4422(17)30435-0CrossRefPubMed

23.

Yazar HO, Yazar T, Aygün A, Kaygisiz Ş, Kirbaş D (2020) Evaluation of simple inflammatory blood parameters in patients with migraine. Ir J Med Sci 189(2):677–683. https://doi.org/10.1007/s11845-019-02136-yCrossRefPubMed

24.

Özge A, Buğdaycı R, Şaşmaz T, Kaleağası H, Kurt Ö, Karakelle A et al (2002) The sensitivity and specificity of the case definition criteria in Mersin. Cephalalgia 22(10):791–798. https://doi.org/10.1046/j.1468-2982.2002.00467.xCrossRefPubMed

25.

Vieru E, Köksal A, Mutluay B, Dirican AC, Altunkaynak Y, Baybas S (2016) The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease. NeurolSci 37(5):743–747. https://doi.org/10.1007/s10072-015-2471-zCrossRef

26.

Yazar HO, Yazar T, Yildirim T, Keşkek A, Altunkaynak Y (2019 Sep) Assessment of serum uric acid levels in patients with restless legs syndrome. Acta Neurol Belg 119(3):461–466. https://doi.org/10.1007/s13760-019-01177-5CrossRefPubMed

27.

Yazar T, Yazar HO (2019) Assessment of serum uric acid levels according to sex and stage for patients with Alzheimer-type dementia. Turk J Neurol 25(2):76–81. https://doi.org/10.4274/tnd.galenos.2019.85698CrossRef

28.

Carvalho AN, Firuzi O, Gama MJ, Horssen JV, Saso L (2017) Oxidative stress and antioxidants in neurological diseases: is there still hope? Curr Drug Targets 18(6):705–718. https://doi.org/10.2174/1389450117666160401120514CrossRefPubMed

29.

Tekeşin A, Tunç A (2019) Evaluation of inflammatory markers in patients with migraine. Arch Clin Exp Med 4(1):37–40. https://doi.org/10.25000/acem.494415CrossRef

30.

Shimomura T, Kowa H, Nakamo T, Kitano A, Marukawa H, Urakami K, Takahashi K (1994) Platelet superoxide dismutase in migraine and tension-type headache. Cephalalgia 14(3):215–218. https://doi.org/10.1046/j.1468-2982.1994.014003215.xCrossRefPubMed

31.

Moschiano F, D’Amico D, Usai S et al (2008) Homocysteine plasma levels in patients with migraine with aura. Neurol Sci 29(suppl 1):S173–S175. https://doi.org/10.1007/s10072-008-0917-2CrossRefPubMed

32.

Nelson KB, Richardson AK, He J, Lateef TM, Khoromi S, Merikangas KR (2010) Headache and biomarkers predictive of vascular disease in a representative sample of US children. Arch Pediatr Adolesc Med 164(4):358–362. https://doi.org/10.1001/archpediatrics.2010.17CrossRefPubMedPubMedCentral

33.

Yilmaz N, Aydin O, Yegin A, Tiltak A, Eren E (2011) Increased levels of total oxidant status and decreased activity of arylesterase in migraineurs. Clin Biochem 44(10–11):832–837. https://doi.org/10.1016/j.clinbiochem.2011.04.015CrossRefPubMed

34.

Erol I, Alehan F, Aldemir D, Ogus E (2010) Increased vulnerability to oxidative stress in pediatric migraine patients. Pediatr Neurol 43(1):21–24. https://doi.org/10.1016/j.pediatrneurol.2010.02.014CrossRefPubMed

35.

Lipton RB, Silberstein SD (2015) Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache 55(Suppl2):103–122; quiz 123-6. https://doi.org/10.1111/head.12505_2CrossRefPubMed

36.

Weatherall MW (2015) The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis 6(3):115–123. https://doi.org/10.1177/2040622315579627CrossRefPubMedPubMedCentral

37.

Buse DC, Greisman JD, Baigi K, Lipton RB (2019) Migraine progression: a systematic review. Headache 59(3):306–338. https://doi.org/10.1111/head.13459 Epub 2018 Dec 27CrossRefPubMed

38.

Hayne DP, Martin PR (2019) Relating photophobia, visual aura, and visual triggers of headache and migraine. Headache 59(3):430–442. https://doi.org/10.1111/head.13486CrossRefPubMed

39.

Shatillo A, Koroleva K, Giniatullina R, Naumenko N, Slastnikova AA, Aliev RR, Bart G, Atalay M, Gu C, Khazipov R, Davletov B, Grohn O, Giniatullin R (2013) Cortical spreading depression induces oxidative stress in the trigeminal nociceptive system. Neuroscience 253:341–349. https://doi.org/10.1016/j.neuroscience.2013.09.002CrossRefPubMed

40.

Bokhari FA, Shakoori TA, Hassan SA, Qureshi HJ, Qureshi GA (2010) Plasma homocysteine in patients of migraine without aura. J Ayub Med Coll Abbottabad 22(2):52–55PubMed

Title: Evaluation of serum uric levels in migraine
Authors: Tamer Yazar
Hülya Olgun Yazar
Ali Aygün
Volkan Karabacak
Yavuz Altunkaynak
Dursun Kirbaş
Publication date: 01-02-2021
Publisher: Springer International Publishing
Keywords: Migraine
Aura
Headache
Published in: Neurological Sciences / Issue 2/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04598-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of serum uric levels in migraine

Abstract

Objective

Method

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2021

Correction to: Lymphocyte-to-monocyte ratio and risk of hemorrhagic transformation in patients with acute ischemic stroke

Coffin-Siris syndrome and epilepsy

Spasmodic cough preceding CANVAS phenotype in a family with biallelic repeat expansions in RFC1

Down’s syndrome and COVID-19: risk or protection factor against infection? A molecular and genetic approach

Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction

Hyperkinetic manifestations in superficial siderosis: evidence for pathogenic network disruption